Pharmaceuticals and Healthcare - Drug Manufacturers (Specialty & Generic)
Strategic Profile
As a subsidiary of Abbott Laboratories, the company develops and distributes science-based products across diverse therapeutic areas including women's health, gastroenterology, cardiology, metabolic disorders, and primary care. The company is almost debt-free with strong profitability, delivering 19.0% profit growth CAGR over five years and maintaining a healthy dividend payout of 72.2%.
Cyborg Score Rationale
With a market cap of $7.01B and strong fundamentals including zero debt, Abbott India demonstrates solid operational strength and returns to shareholders. However, the company has delivered poor sales growth of 9.38% over the past five years, indicating limited expansion momentum in a competitive market.
Top Insights
Market cap of $7.01B with TTM revenue of $781M, reflecting strong operational profitability
Nearly debt-free balance sheet with 3-year ROE of 34.2%, indicating excellent capital efficiency
Sales growth of only 9.38% CAGR over five years suggests saturation in core markets
Founded in 1944, headquartered in Mumbai with 3,659 employees, providing 80+ years of healthcare delivery in India
Named Competitors
Johnson & Johnson — Diversified healthcare products and pharma
Novo Nordisk — Specialty pharmaceutical company
Novartis — Global pharmaceutical and healthcare solutions